|
Weitere Bezeichnung
|
RLC (Regulatory Light Chain of Smooth and Non-Muscle Myosin)
|
|
Swiss-Prot
|
Q9CQ19
|
|
Immunogen
|
This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizationswith a synthetic peptide corresponding to amino acids 12-27 of human myosin light chain protein.
|
|
Format
|
Liquid (sterile filtered)
|
|
Beschreibung
|
Myosin is the majorcomponent of thick muscle filaments, and is along asymmetric molecule containing a globularhead and a long tail. The molecule consists oftwo heavy chains each ~200,000 daltons, andfour light chains each ~16,000 - 21,000 daltons.Activation of smooth and cardiac muscleprimarily involves pathways that increasecalcium and myosin phosphorylation resulting incontraction. Myosin light chain phosphataseacts to regulate muscle contraction bydephosphorylating activated myosin light chain.The selected peptide sequence used to generatethe polyclonal antibody is located near the aminoterminal end of the polypeptide corresponding tothe smooth/non-muscle form of myosinregulatory light chain found in cardiac myocytesin addition to smooth and non-muscle cells. Thissequence differs from that of the sarcomeric/ cardiac form of myosin regulatory light chain that has a different sequence around the phosphorylation site. Human,mouse and rat have almost identical sequences.
|
|
Spezifität
|
This affinity purified antibody is directed against the regulatory light chain of smooth and non-muscle myosin. The antibody detects both unphosphorylated and monophosphorylated forms of the protein. Theproduct was affinity purified from monospecific antiserum by immunoaffinity purification. Cross reactivity is expectedwith myosin light chain from human, mouse and rat sources. Reactivity with the protein from other species has notbeen determined, however, the sequence of the immunogen is nearly identical in mammalian and avian species.BLAST search analysis was used to determine that the smooth and non-muscle forms of myosin regulatory light chainhave identical sequences. Cross reactivity is expected. Protein Sequence: Human RLCM, 172 aa, predicted MW 19.8 kDa 1 msskrakakt tkkrpqrats nvfamfdqsq iqefkeafnm idqnrdgfid kedlhdmlas 61 lgknptdeyl egmmseapgp inftmfltmf geklngtdpe dvirnafacf deeasgfihe 121 dhlrellttm gdrftdeevd emyreapidk kgnfnyveft rilkhgakdk dd
|